{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T12:21:00Z","timestamp":1780143660160,"version":"3.54.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Zhejiang Provincial Clinical Research Program of Traditional Chinese Medicin","award":["2024ZL103"],"award-info":[{"award-number":["2024ZL103"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-74792-9","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T11:02:10Z","timestamp":1728558130000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A screening study of high-risk groups for liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease"],"prefix":"10.1038","volume":"14","author":[{"given":"Guanqun","family":"Chao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"issue":"1","key":"74792_CR1","first-page":"174","volume":"11","author":"J Ji","year":"2023","unstructured":"Ji, J., Wu, L., Wei, J., Wu, J. & Guo, C. The gut microbiome and ferroptosis in MAFLD. J. Clin. Transl. Hepatol. 11(1), 174\u2013187 (2023).","journal-title":"J. Clin. Transl. Hepatol."},{"issue":"5","key":"74792_CR2","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1097\/CM9.0000000000002089","volume":"135","author":"SDW Bae","year":"2022","unstructured":"Bae SDW, George J, Qiao L. From MAFLD to hepatocellular carcinoma and everything in between. Chin. Med. J. (Engl). 135(5):547\u2013556 (2022).","journal-title":"Chin. Med. J. (Engl)"},{"issue":"2","key":"74792_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.14218\/JCTH.2021.00178","volume":"10","author":"E Kaya","year":"2022","unstructured":"Kaya, E. & Yilmaz, Y. Metabolic-associated fatty liver disease (MAFLD): A multi-systemic disease beyond the liver. J. Clin. Transl. Hepatol. 10(2), 329\u2013338 (2022).","journal-title":"J. Clin. Transl. Hepatol."},{"issue":"4","key":"74792_CR4","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3390\/cells9040875","volume":"9","author":"N Roehlen","year":"2020","unstructured":"Roehlen, N., Crouchet, E. & Baumert, T. F. Liver fibrosis: Mechanistic concepts and therapeutic perspectives. Cells. 9(4), 875 (2020).","journal-title":"Cells."},{"issue":"2","key":"74792_CR5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.gtc.2019.02.002","volume":"48","author":"M Lai","year":"2019","unstructured":"Lai, M. & Afdhal, N. H. Liver fibrosis determination. Gastroenterol. Clin. N. Am. 48(2), 281\u2013289 (2019).","journal-title":"Gastroenterol. Clin. N. Am."},{"key":"74792_CR6","doi-asserted-by":"publisher","first-page":"761538","DOI":"10.3389\/fmed.2021.761538","volume":"8","author":"W Qu","year":"2021","unstructured":"Qu, W. et al. Liver fibrosis and MAFLD: From molecular aspects to novel pharmacological strategies. Front. Med. (Lausanne) 8, 761538 (2021).","journal-title":"Front. Med. (Lausanne)"},{"key":"74792_CR7","doi-asserted-by":"publisher","first-page":"951689","DOI":"10.3389\/fendo.2022.951689","volume":"13","author":"Y Xue","year":"2022","unstructured":"Xue, Y., Xu, J., Li, M. & Gao, Y. Potential screening indicators for early diagnosis of NAFLD\/MAFLD and liver fibrosis: Triglyceride glucose index-related parameters. Front. Endocrinol. (Lausanne) 13, 951689 (2022).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"74792_CR8","doi-asserted-by":"publisher","first-page":"1120621","DOI":"10.3389\/fmed.2023.1120621","volume":"10","author":"Q Dong","year":"2023","unstructured":"Dong, Q. et al. Liver fibrosis and MAFLD: The exploration of multi-drug combination therapy strategies. Front. Med. (Lausanne) 10, 1120621 (2023).","journal-title":"Front. Med. (Lausanne)"},{"issue":"23","key":"74792_CR9","first-page":"11402","volume":"27","author":"HF Zhang","year":"2023","unstructured":"Zhang, H. F., Zhang, Q. X., Feng, Y. H., Li, S. J. & Xie, B. Y. Association of thyroid disease and risk of fatty liver disease: An exposure-wide mendelian randomization study. Eur. Rev. Med. Pharmacol. Sci. 27(23), 11402\u201311411 (2023).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"74792_CR10","doi-asserted-by":"crossref","unstructured":"Li, D., Zhang, Z., Zhang, C., Guo, Q., Chen, C., Peng, X. Unraveling the connection between Hashimoto\u2019s Thyroiditis and non-alcoholic fatty liver disease: exploring the role of CD4(+)central memory T cells through integrated genetic approaches. Endocrine. (2024).","DOI":"10.1007\/s12020-024-03745-z"},{"issue":"1","key":"74792_CR11","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam, M. et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J. Hepatol. 73(1), 202\u2013209 (2020).","journal-title":"J. Hepatol."},{"issue":"2","key":"74792_CR12","first-page":"143","volume":"11","author":"Y Sumida","year":"2021","unstructured":"Sumida, Y. et al. First in the diagnostic algorithm of metabolic-dysfunction-associated fatty liver disease in the era of the global metabodemic. Life (Basel) 11(2), 143 (2021).","journal-title":"Life (Basel)"},{"issue":"6","key":"74792_CR13","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.3390\/nu14061224","volume":"14","author":"L Li","year":"2022","unstructured":"Li, L. et al. The association between non-alcoholic fatty liver disease (NAFLD) and advanced fibrosis with serological vitamin B12 markers: Results from the NHANES 1999\u20132004. Nutrients 14(6), 1224 (2022).","journal-title":"Nutrients"},{"issue":"10","key":"74792_CR14","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s00535-023-02021-7","volume":"58","author":"H Crane","year":"2023","unstructured":"Crane, H., Gofton, C., Sharma, A. & George, J. MAFLD: An optimal framework for understanding liver cancer phenotypes. J. Gastroenterol. 58(10), 947\u2013964 (2023).","journal-title":"J. Gastroenterol."},{"key":"74792_CR15","doi-asserted-by":"publisher","first-page":"204201882211456","DOI":"10.1177\/20420188221145650","volume":"14","author":"SC Pal","year":"2023","unstructured":"Pal, S. C. & M\u00e9ndez-S\u00e1nchez, N. Screening for MAFLD: Who, when and how?. Ther. Adv. Endocrinol. Metab. 14, 20420188221145650 (2023).","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"74792_CR16","doi-asserted-by":"publisher","first-page":"774079","DOI":"10.3389\/fmed.2021.774079","volume":"8","author":"NL\u00c1 Segura-Azuara","year":"2022","unstructured":"Segura-Azuara, N. L. \u00c1., Varela-Chinchilla, C. D. & Trinidad-Calder\u00f3n, P. A. MAFLD\/NAFLD biopsy-free Scoring systems for hepatic steatosis, NASH, and fibrosis diagnosis. Front. Med. (Lausanne) 8, 774079 (2022).","journal-title":"Front. Med. (Lausanne)"},{"issue":"2","key":"74792_CR17","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1535370219898141","volume":"245","author":"D Dhar","year":"2020","unstructured":"Dhar, D., Baglieri, J., Kisseleva, T. & Brenner, D. A. Mechanisms of liver fibrosis and its role in liver cancer. Exp. Biol. Med. (Maywood) 245(2), 96\u2013108 (2020).","journal-title":"Exp. Biol. Med. (Maywood)"},{"issue":"1","key":"74792_CR18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12944-023-01947-4","volume":"22","author":"Q Liu","year":"2023","unstructured":"Liu, Q. et al. Shift in prevalence and systemic inflammation levels from NAFLD to MAFLD: A population-based cross-sectional study. Lipids Health Dis. 22(1), 185 (2023).","journal-title":"Lipids Health Dis."},{"issue":"6","key":"74792_CR19","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.pcd.2021.08.015","volume":"15","author":"S Bilgin","year":"2021","unstructured":"Bilgin, S. et al. Does C-reactive protein to serum albumin ratio correlate with diabetic nephropathy in patients with type 2 dIabetes mellitus? The care time study. Prim. Care Diabetes 15(6), 1071\u20131074 (2021).","journal-title":"Prim. Care Diabetes"},{"issue":"6","key":"74792_CR20","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1590\/1806-9282.20220236","volume":"68","author":"ME Demirkol","year":"2022","unstructured":"Demirkol, M. E. et al. C-reactive protein to lymphocyte count ratio is a promising novel marker in hepatitis C infection: The clear hep-c study. Rev. Assoc. Med. Bras. (1992) 68(6), 838\u2013841 (2022).","journal-title":"Rev. Assoc. Med. Bras. (1992)"},{"issue":"4","key":"74792_CR21","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1590\/1806-9282.20201005","volume":"67","author":"MA Kosekli","year":"2021","unstructured":"Kosekli, M. A. et al. The association between serum uric acid to high density lipoprotein-cholesterol ratio and non-alcoholic fatty liver disease: The abund study. Rev. Assoc. Med. Bras. (1992) 67(4), 549\u2013554 (2021).","journal-title":"Rev. Assoc. Med. Bras. (1992)"},{"issue":"2","key":"74792_CR22","first-page":"277","volume":"62","author":"MA Kosekli","year":"2023","unstructured":"Kosekli, M. A. & Aktas, G. Serum uric acid to HDL cholesterol ratio is associated with diabetic control in new onset type 2 diabetic population. Acta Clin. Croat. 62(2), 277\u2013282 (2023).","journal-title":"Acta Clin. Croat."},{"issue":"8","key":"74792_CR23","doi-asserted-by":"publisher","first-page":"675","DOI":"10.3390\/metabo12080675","volume":"12","author":"RA Marschner","year":"2022","unstructured":"Marschner, R. A., Arenhardt, F., Ribeiro, R. T. & Wajner, S. M. Influence of altered thyroid hormone mechanisms in the progression of metabolic dysfunction associated with fatty liver disease (MAFLD):\u00a0A systematic review. Metabolites 12(8), 675 (2022).","journal-title":"Metabolites"},{"issue":"10","key":"74792_CR24","doi-asserted-by":"publisher","first-page":"102649","DOI":"10.1016\/j.autrev.2020.102649","volume":"19","author":"M Ralli","year":"2020","unstructured":"Ralli, M. et al. Hashimoto\u2019s thyroiditis: an update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential malignant transformation. Autoimmun. Rev. 19(10), 102649 (2020).","journal-title":"Autoimmun. Rev."},{"issue":"5","key":"74792_CR25","doi-asserted-by":"publisher","first-page":"e1135","DOI":"10.1016\/j.cgh.2021.06.042","volume":"20","author":"W Sohn","year":"2022","unstructured":"Sohn, W., Kwon, H. J., Chang, Y., Ryu, S. & Cho, Y. K. Liver fibrosis in asians with metabolic dysfunction-associated fatty liver disease. Clin. Gastroenterol. Hepatol. 20(5), e1135\u2013e1148 (2022).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"11","key":"74792_CR26","doi-asserted-by":"publisher","first-page":"300060521105684","DOI":"10.1177\/03000605211056841","volume":"49","author":"F T\u00fcrker","year":"2021","unstructured":"T\u00fcrker, F. et al. Does the FT3-to-FT4 ratio easily predict the progression of NAFLD and NASH cirrhosis?J. Int. Med. Res. 49(11), 3000605211056841 (2021).","journal-title":"Int. Med. Res."},{"key":"74792_CR27","doi-asserted-by":"publisher","first-page":"1403720","DOI":"10.3389\/fnut.2024.1403720","volume":"11","author":"D Liang","year":"2024","unstructured":"Liang, D. et al. Associations of life\u2019s essential 8 with MAFLD and liver fibrosis among US adults: A nationwide cross-section study. Front. Nutr. 11, 1403720 (2024).","journal-title":"Front. Nutr."},{"issue":"1","key":"74792_CR28","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41392-024-01797-1","volume":"9","author":"YF Wang","year":"2024","unstructured":"Wang, Y. F. et al. METTL14 downregulation drives S100A4(+) monocyte-derived macrophages via MyD88\/NF-kappaB pathway to promote MAFLD progression. Signal Transduct. Target Ther. 9(1), 91 (2024).","journal-title":"Signal Transduct. Target Ther."},{"issue":"2","key":"74792_CR29","doi-asserted-by":"publisher","first-page":"100892","DOI":"10.1016\/j.aohep.2022.100892","volume":"28","author":"J Liu","year":"2023","unstructured":"Liu, J. et al. Blood pressure stratification for predicting liver fibrosis risk in metabolic dysfunction associated fatty liver disease. Ann. Hepatol. 28(2), 100892 (2023).","journal-title":"Ann. Hepatol."},{"issue":"2","key":"74792_CR30","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/hepr.13728","volume":"52","author":"S Yang","year":"2022","unstructured":"Yang, S. et al. Metabolic dysfunction-associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle-aged and older US population. Hepatol. Res. 52(2), 176\u2013186 (2022).","journal-title":"Hepatol. Res."},{"key":"74792_CR31","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.2147\/DMSO.S426102","volume":"16","author":"C Lu","year":"2023","unstructured":"Lu, C., Chen, Y., Zhang, Y. & Zhao, X. Liver fibrosis scores and coronary artery disease: novel findings in patients with metabolic dysfunction-associated fatty liver disease. Diabetes Metab. Syndr. Obes. 16, 2627\u20132637 (2023).","journal-title":"Diabetes Metab. Syndr. Obes."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74792-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74792-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74792-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T15:02:03Z","timestamp":1728831723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74792-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["74792"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-74792-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,10]]},"assertion":[{"value":"21 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study has been reviewed by the Ethics Committee of Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, and the approval number is Sir Run Run Shaw Hospital Ethics Review 2024 Yan No. 0296. The data of this study were obtained from the database of physical examination centers and the consent of the physical examiners.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"N\/A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"23714"}}